Moderna sued Pfizer Aug. 26 for allegedly infringing three of its patents related to messenger RNA, the genetic material at the heart of their vaccines. Attorneys and academics say the move heralds a shift in the future of mRNA technologies.
The company’s patents may cover technology that proves important in future vaccines as well. If it prevails against Pfizer, Moderna will be in a stronger position to license ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.